Compound
D1002 | mifepristone
G
G03XB01 Mifepristone
[G03XB] Progesterone receptor modulators
[G03X] OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
[G03] SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
[G] Genitourinary system and reproductive hormones
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 16.13±32.54 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | human | HepG2 | MMP assay | Negative | IC50 | 163 | ||
| MEMBRANE POTENTIAL | rat | hepatocytes | MMP assay | Negative | IC50 | 163 | ||
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
  |
Danger |
Aggregated GHS information provided by 59 companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H302 (28.81%): Harmful if swallowed [Warning Acute toxicity, oral] H312 (28.81%): Harmful in contact with skin [Warning Acute toxicity, dermal] H332 (28.81%): Harmful if inhaled [Warning Acute toxicity, inhalation] H360 (98.31%): May damage fertility or the unborn child [Danger Reproductive toxicity] H362 (27.12%): May cause harm to breast-fed children [Reproductive toxicity, effects on or via lactation] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P201, P202, P260, P261, P263, P264, P270, P271, P280, P281, P301+P312, P302+P352, P304+P312, P304+P340, P308+P313, P312, P322, P330, P363, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| (10S,11S,14S,15S,17R)-17-[4-(dimethylamino)phenyl]-14-hydroxy-15-methyl-14-(prop-1-yn-1-yl)tetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-1,6-dien-5-one | (10S,11S,14S,15S,17R)-17-[4-(dimethylamino)phenyl]-14-hydroxy-15-methyl-14-(prop-1-yn-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-1,6-dien-5-one | (11?,17?)-11-[4-(Dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one |
| (11R,13S,14S,17S)-11-(4-Dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one | (11beta,17beta)-11-(4-(Dimethylamino)-phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one | (11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one |
| (11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one | (11beta,17beta)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-prop-1-yn-1-ylestra-4,9-dien-3-one | (8S,11R,13S,14S,17S)-11-(4-(dimethylamino)phenyl)-17-hydroxy-13-methyl-17-(prop-1-yn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one |
| (8S,11R,13S,14S,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one | (8S,11R,13S,14S,17S)-11-[4-(Dimethylamino)phenyl]-17-hydroxy-13-methyl-17-(prop-1-yn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one (non-preferred name) | (8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-13-methyl-17-oxidanyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one |
| (8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one | (non-labelled)Mifepristone-d3 | 11-(4-DIMETHYLAMINO-PHENYL)-17-HYDROXY-13-METHYL-17-PROP-1-YNYL-1,2,6,7,8,11,12,13,14,15,16,17-DODEC AHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE |
| 11.beta.-[4-(Dimethylamino)phenyl]-17.beta.-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one | 11beta-(4-(Dimethylamino)phenyl)-17-hydroxy-21-methyl-19-nor-17alpha-pregna-4,9-dien-20-m-3-on | 11beta-(4-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-on |
| 11beta-(4-(N,N-Dimethylamino)phenyl)-17alpha-(prop-1-ynyl)-delta4,9-estradiene-17beta-ol-3-one | 11beta-(4-Dimethyl-amino)-phenyl-17beta-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one | 11beta-(p-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one |
| 11ss-[p-(Dimethylamino)fenyl]-17ss-hydroxy- 17-(1-propynyl)estra-4,9-dien-3-on | 17-beta-Hydroxy-11-beta-(4-dimethylaminophenyl-1)-17-alpha-(prop-1-ynyl)oestra-4,9-dien-3-one | 1nhz |
| 29523-EP2272827A1 | 29523-EP2275420A1 | 29523-EP2295055A2 |
| 29523-EP2295416A2 | 29523-EP2298748A2 | 29523-EP2298764A1 |
| 29523-EP2298765A1 | 29523-EP2305642A2 | 29523-EP2308880A1 |
| 29523-EP2311453A1 | 29523-EP2311808A1 | 29523-EP2311829A1 |
| 29523-EP2311842A2 | 2w8y | 320T6RNW1F |
| 371M653 | 75603-EP2269977A2 | 75603-EP2308880A1 |
| 83203-42-3 | 84371-65-3 | A840767 |
| AB2000695 | ABP000437 | ACT02598 |
| AKOS015895416 | ANW-41472 | AOB6893 |
| API0003390 | ARONIS27015 | AS-13938 |
| BCP02145 | BDBM18627 | BDBM50072024 |
| BIDD:PXR0123 | BPBio1_000262 | BRD-K37270826-001-04-5 |
| BRD-K37270826-001-31-8 | BRN 5779404 | BSPBio_000238 |
| C-1073 | C07652 | C29H35NO2 |
| CAS-84371-65-3 | CCG-101164 | CCRIS 9332 |
| CHEBI:50692 | CHEMBL1276308 | CHEMBL438575 |
| CI-1073 | CPD000058481 | CS-1435 |
| CTK8B2959 | Corlux | D00585 |
| DB00834 | DSSTox_CID_3322 | DSSTox_GSID_23322 |
| DSSTox_RID_76976 | DTXSID5023322 | EU-0100801 |
| Estra-4,9-dien-3-one, 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-, (11-beta,17-beta)- | Estra-4,9-dien-3-one, 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-, (11beta,17beta)- | Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-, (11b,17b)-; |
| FT-0082666 | FT-0602519 | GTPL2805 |
| HMS1568L20 | HMS2052L05 | HMS2090L22 |
| HMS2095L20 | HMS2230P21 | HMS3262B03 |
| HMS3412D17 | HMS3649J08 | HMS3676D17 |
| HMS3712L20 | HSCI1_000369 | HSDB 6841 |
| HY-13683 | Korlym | Korlym (TN) |
| LP00801 | LS-64723 | Lopac0_000801 |
| M 8046 | MFCD00867226 | MLS000069785 |
| MLS001074115 | MLS001424271 | Mifegyne |
| Mifeprex | Mifeprex (TN) | Mifepriston |
| Mifepristona | Mifepristona [Spanish] | Mifepristone (JAN/USAN/INN) |
| Mifepristone (Mifeprex) | Mifepristone 1.0 mg/ml in Acetonitrile | Mifepristone [USAN:INN:BAN] |
| Mifepristone(Mifeprex) | Mifepristone(Mifeprex)/ | Mifepristone, 98% |
| Mifepristone, >=98% | Mifepristone, United States Pharmacopeia (USP) Reference Standard | Mifepristonum |
| Mifepristonum [Latin] | NC00414 | NCGC00025179-05 |
| NCGC00025179-06 | NCGC00025179-07 | NCGC00025179-08 |
| NCGC00025179-09 | NCGC00025179-12 | NCGC00025179-13 |
| NCGC00179632-01 | NCGC00255152-01 | NCGC00261486-01 |
| Opera_ID_562 | Pictovir | Pictovir (TM) |
| Prestwick0_000299 | Prestwick1_000299 | Prestwick2_000299 |
| Prestwick3_000299 | Prestwick_570 | Q-201405 |
| Q411240 | R 38486 | R-38486 |
| R38486 | RU 38486 | RU 486 |
| RU 486-6 | RU-38486 | RU-486 |
| RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex | RU486 | RU486 (tetramethyl-rhodamine conjugated) |
| RU486;C-1073 | SC-16222 | SCHEMBL16087 |
| SMR000058481 | SPBio_002457 | SR-01000076011 |
| SR-01000076011-1 | SR-01000076011-3 | SR-01000076011-5 |
| SR-01000076011-9 | SR-01000721888 | SR-01000721888-4 |
| Spectrum5_002045 | TR-026092 | Tox21_110952 |
| Tox21_110952_1 | Tox21_301841 | Tox21_500801 |
| UNII-320T6RNW1F | VGX-410 | VGX-410C |
| VKHAHZOOUSRJNA-GCNJZUOMSA-N | VX-410 | W-5163 |
| ZINC3831128 | ZK-98296 | ZK98296 |
| mifepristone | s2606 |